A multiple-site, phase 1/2, safety, and efficacy trial of a recombinant adeno-associated virus vector expressing retinoschisin (rAAV2tYF-CB-hRS1) in patients with X-linked retinoschisis. The gene discussed is RS1; the disease is X-linked retinoschisis.